Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $24.1 million.

  • Ligand Pharmaceuticals' Accumulated Expenses rose 54.38% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 54.38%. This contributed to the annual value of $27.9 million for FY2024, which is 123.84% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Accumulated Expenses is $24.1 million, which was up 37.91% from $17.5 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Accumulated Expenses' 5-year high stood at $27.9 million during Q4 2024, with a 5-year trough of $7.3 million in Q2 2023.
  • Moreover, its 3-year median value for Accumulated Expenses was $15.0 million (2023), whereas its average is $16.2 million.
  • In the last 5 years, Ligand Pharmaceuticals' Accumulated Expenses tumbled by 49.89% in 2023 and then soared by 123.84% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $17.6 million in 2021, then fell by 10.80% to $15.7 million in 2022, then fell by 20.50% to $12.5 million in 2023, then skyrocketed by 123.84% to $27.9 million in 2024, then skyrocketed by 54.38% to $24.1 million in 2025.
  • Its last three reported values are $24.1 million in Q3 2025, $17.5 million for Q2 2025, and $23.5 million during Q1 2025.